Acumen Pharmaceuticals, Inc.

Equities

ABOS

US00509G2093

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 03:28:14 2024-04-19 pm EDT			5-day change	1st Jan Change
3.125 ^USD	-1.11%		-17.11%	-19.27%

Apr. 04	Acumen Pharmaceuticals Signs Deal With Lonza to Manufacture Alzheimer's Treatment Drug	MT
Apr. 04	Lonza Enters Manufacturing Agreement for Acumen’s Alzheimer’s Disease Drug Candidate	MT

Acumen Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022

August 15, 2022 at 05:19 pm EDT

Acumen Pharmaceuticals, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported net loss was USD 10.15 million compared to USD 61.36 million a year ago. Basic loss per share from continuing operations was USD 0.25 compared to USD 141.93 a year ago.
For the six months, net loss was USD 19.28 million compared to USD 88.36 million a year ago. Basic loss per share from continuing operations was USD 0.48 compared to USD 207.52 a year ago.

Latest news about Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals Signs Deal With Lonza to Manufacture Alzheimer's Treatment Drug	Apr. 04	MT
Lonza Enters Manufacturing Agreement for Acumen’s Alzheimer’s Disease Drug Candidate	Apr. 04	MT
Acumen Pharmaceuticals, Inc. Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer?S Disease	Apr. 04	CI
Acumen Pharmaceuticals Files $200 Million Mixed Shelf	Mar. 27	MT
Acumen Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26	CI
Transcript : Acumen Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 26, 2024	Mar. 26
Acumen Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26	CI
Acumen Pharmaceuticals, Inc. Presents Sabirnetug Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer's At the AD/PD 2024 Annual Meeting	Mar. 08	CI
Acumen Pharmaceuticals, Inc. Appoints James Doherty as Its President and Chief Development Officer	Feb. 01	CI
Transcript : Acumen Pharmaceuticals, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 10:30 AM	Jan. 11
Acumen Pharmaceuticals, Inc.(NasdaqGS:ABOS) dropped from NASDAQ Biotechnology Index	Dec. 15	CI
Deutsche Bank Initiates Coverage on Acumen Pharmaceuticals With Buy Rating, $8 Price Target	Dec. 12	MT
Acumen Pharmaceuticals Secures $50 Million Credit Facility	Nov. 13	MT
Transcript : Acumen Pharmaceuticals, Inc., Q3 2023 Earnings Call, Nov 13, 2023	Nov. 13
Acumen Pharmaceuticals Secures $50.0 Million Credit Facility with K2 HealthVentures	Nov. 13	CI
Acumen Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Acumen Pharmaceuticals, Inc. announced that it expects to receive $50 million in funding	Nov. 12	CI
Transcript : Acumen Pharmaceuticals, Inc. Presents at UBS Biopharma Conference 2023, Nov-09-2023 10:00 AM	Nov. 09
Halozyme Therapeutics Signs Non-Exclusive License Deal With Acumen Pharmaceuticals for Enhanze Technology	Nov. 06	MT
Acumen Pharmaceuticals, Inc. Presents Late-Breaker Phase 1 Updates Exploring Novel Target Engagement, Dosing Regimen and Safety Findings for ACU193 in Early Alzheimer's Disease at the 16th Annual Clinical Trials on Alzheimer's Disease	23-10-27	CI
Acumen Pharmaceuticals, Inc. to Present Deeper Insights from First-In-Human Phase 1 Study of ACU193 for Early Alzheimer?s During Symposium At the 16Th Annual Clinical Trials on Alzheimer?s Disease	23-10-04	CI
Certain Stock Options of Acumen Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 17-SEP-2023.	23-09-16	CI
Certain Common Stock of Acumen Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 17-SEP-2023.	23-09-16	CI
UBS Adjusts Acumen Pharmaceuticals Price Target to $15 From $16, Maintains Buy Rating	23-08-09	MT
Transcript : Acumen Pharmaceuticals, Inc., Q2 2023 Earnings Call, Aug 08, 2023	23-08-08

Chart Acumen Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a disease-modifying approach to target underlying cause of Alzheimer's disease (AD). The Company is focused on advancing a targeted immunotherapy drug candidate, ACU193, and establishing proof of mechanism in early AD patients. The Company's ACU193 is a humanized monoclonal antibody that selectively targets the anti-amyloid-beta oligomer (AbOs), has demonstrated functional and protective effects in in-vitro assays, and has demonstrated in-vivo safety and pharmacologic activity in multiple animal species including transgenic models for AD. The Company's therapeutic approach focuses on targeting AbOs, which is a toxic and pathogenic form of Ab relative to Ab monomers and amyloid plaques. The Company is developing ACU193 for intravenous (IV), administration every four weeks for the treatment of early AD, which is in Phase I clinical trial.

Sector

Biotechnology & Medical Research

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.16 USD

Average target price

12.8 USD

Spread / Average Target

+305.06%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ACUMEN PHARMACEUTICALS, INC.	-19.27%	190M
IQVIA HOLDINGS INC.	-2.22%	41.35B
LONZA GROUP AG	+42.15%	40.38B
MODERNA, INC.	+1.07%	39.05B
CELLTRION, INC.	-14.19%	26.67B
ICON PUBLIC LIMITED COMPANY	+1.53%	24.07B
ALNYLAM PHARMACEUTICALS, INC.	-24.71%	18.36B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-4.25%	11.68B
MEDPACE HOLDINGS, INC.	+20.39%	11.6B
UNITED THERAPEUTICS CORPORATION	+7.82%	11.15B

Other Biotechnology & Medical Research